B+
Bull case
30%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
NTLA
Intellia TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA acceptance and Priority Review make the March 2027 lonvo-z decision concrete, while positive HAELO efficacy and the planned launch support substantial upside if approval and uptake follow [#8-K-2026-09-08] [#SEC-8K-2026-08-06]. The deterministic prior is positive, but these outcomes remain conditional.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.3.
What can break
Cash runway is a company expectation, not a financing guarantee; Intellia remains exposed to clinical and prelaunch spending [#SEC-8K-2026-08-06].
Momentum
53
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $21.00 · Bear $6.50Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $22.88
Why
Momentum53 · Δ7d -14.7
Value41 · Δ7d -0.1
Sentiment84 · Δ7d +2.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.3.
Contradictions & invalidation
- • Cash runway is a company expectation, not a financing guarantee; Intellia remains exposed to clinical and prelaunch spending [#SEC-8K-2026-08-06].
- • Commercial demand, reimbursement and launch execution for a one-time HAE therapy remain unproven.
- • A negative FDA decision, launch friction or another nex-z trial setback could materially impair a concentrated development-stage thesis.
Catalyst clock
2026-12-31
Nex-z Phase 3 enrollment
Lead driver: Sentiment · See AI snapshot
Momentum
53
8% active weight
Current posture
7d trendSoftening
Δ7d
-14.7
Δ21d
-6.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
84
45% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+3.0
Why this grade
Composite grade A. Momentum 53.2 / Value 40.6 / Sentiment 84.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.57B
Beta
2.09
Shares Out
140.13M
P/E (TTM) · Derived
-2.9
P/S (TTM)
18.87
P/FCF (TTM) · Derived
-3.83
Rev YoY
-46.2%
EPS YoY
-18.2%
Gross Margin
+74.4%
Op Margin
-711.7%
Net Debt
-$356.56M
Current Ratio
6.65
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data